Adenoviral human BCL-2 transgene expression attenuates early donor cell death after cardiomyoblast transplantation into ischemic rat hearts.

@article{Kutschka2006AdenoviralHB,
  title={Adenoviral human BCL-2 transgene expression attenuates early donor cell death after cardiomyoblast transplantation into ischemic rat hearts.},
  author={Ingo Kutschka and Theodoros Kofidis and Ian Yen-Hung Chen and Georges von Degenfeld and Monika Zwierzchoniewska and Grant Hoyt and Takayasu Arai and Darren R. Lebl and Stephen L. Hendry and Ahmad Y. Sheikh and David Tom Cooke and Andrew Connolly and Helen M. Blau and Sanjiv Sam Gambhir and Robert Clayton Robbins},
  journal={Circulation},
  year={2006},
  volume={114 1 Suppl},
  pages={I174-80}
}
BACKGROUND Cell transplantation for myocardial repair is limited by early cell death. Gene therapy with human Bcl-2 (hBcl-2) has been shown to attenuate apoptosis in the experimental setting. Therefore, we studied the potential benefit of hBcl-2 transgene expression on the survival of cardiomyoblast grafts in ischemic rat hearts. METHODS AND RESULTS H9c2 rat cardiomyoblasts were genetically modified to express both firefly luciferase and green fluorescent protein (mH9c2). The cells were then… CONTINUE READING